New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock

International Journal of Antimicrobial Agents

Volumn 12, Issue 2, 1999, Pages 97-105

  Periti, Piero ^a   Mazzei, Teresita ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antimicrobial chemotherapy; Chemoresistance; Endotoxins; Pharmacodynamics; Pharmacokinetics; Sepsis; Septic shock

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTRIAXONE; ENDOTOXIN; GLYCOPEPTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; DRUG EFFICACY; DRUG INDICATION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SPHEROPLAST;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; ENDOTOXEMIA; ENDOTOXINS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LACTAMS; RISK FACTORS; SHOCK, SEPTIC;

EID: 0033037388     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00044-8     Document Type: Review

References (74)

1. Reilly J., Compagnon A., Tuornier P., Bastin R., DuBuit H. Les accidents du traitment des fievres typhoides par la chloromycetine. Ann. Med. (Paris). 51:1950;597-629.
2. Shenep J.L., Flynn P.M., Barrett F.F., Stidham G.L., Westenkirchner D.F. Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative bacterial sepsis - concise communications. J. Infect. Dis. 157(3):1988;565-568.
3. Finch R.G. Design of clinical trials in sepsis: problems and pitfalls. J. Antimicrob. Chemother. 41:1998;95-102.
4. Vincent J.-L. New therapies in sepsis. Chest. 112:1997;330S-338.
5. Nyström P.-O. The systemic inflammatory response syndrome: definitions and aetiology. J. Antimicrob. Chemother. 41:1998;1-7.
6. Singer M. Management of multiple organ failure: guidelines but no hard-and-fast rules. J. Antimicrob. Chemother. 41:1998;103-112.
7. Hurley J.C., Louis W.J., Tosolini F.A., Carlin J.B. Antibiotic-induced release of endotoxin in chronically bacteriuric patients. Antimicrob. Agents Chemother. 35(11):1991;2388-2394.
8. Jackson J.J., Kroop H. lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J. Infect. Dis. 165:1992;1033-1041.
9. Hurley J.C. Antibiotic-induced release of endotoxin: a reappraisal. Clin. Infect. Dis. 15:1992;840-854.
10. Bucklin S.E., Fujihara Y., Leeson M.C., Morrison D.C. Differential antibiotic-induced release of endotoxin from Gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 13(Suppl 1):1994;43-51.
11. Nitsche D., Schulze C., Oesser S., Dalhoff A., Sack M. Impact of different classes of antimicrobial agents on plasma endotoxin activity. Arch. Surg. 131:1996;192-199.
12. Horn D.L., Opal S.M., Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in Gram-negative sepsis. Scand. J. Infect. Dis. 101(Suppl.):1996;9-13.
13. Kirikae T., Nakano M., Morrison D.C. Antibiotic-induced endotoxin release from bacteria and its clinical significance - Review. Microbiol. Immunol. 41(4):1997;285-294.
14. Periti P., Mazzei T., De Gaudio A.R., Tonelli F. Attuali orientamenti nella scelta e modalità di somministrazione degli agenti antimicrobici per una razionale chemioterapia della sepsi grave. Farm. Ter. XV(1/2):1998;3-23.
15. Stuertz K., Schmidt H., Eiffert H., Schwartz P., Mäder M., Nau R. Differential release of lipoteichoic and teichoic acids from Streptococcus penumoniae as a result of exposure to β-lactam antibiotics, rifamycins, trovafloxacin, quinupristin-dalfopristin. Antimicrob. Agents Chemother. 42(2):1998;277-281.
16. Mattsson E.L., Verhage L., Rollof K., Fleer A., Verhoef J., Van Dijk H. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor α, interleukin-1β and interleukin-6. FEMS Immunol. Med. Microbiol. 7:1993;281-288.
17. Timmerman C.P., Mattson E., Martinez-Martinez L. et al. Induction of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect. Immun. 61:1993;4167-4172.
18. Frieling J.T.M., Mulder J.A., Hendriks T., Curfs J.H.A.J., Van der Linden C.J., Sauerwein R.W. Differential induction of pro-and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment. Antimicrob. Agents Chemother. 41(7):1997;1439-1443.
19. Shenep J.L., Mogan K.A. Kinetics of endotoxin release during antibiotic therapy for experimental Gram-negative bacterial sepsis. J. Infect. Dis. 150:1984;380-388.
20. Cohen J., McConnell J.S. Antibiotic-induced endotoxin release. Lancet. 2:1985;1069-1070.
21. Shenep J.L., Barton R.P., Mogan K.A. Role or antibiotic class in the rate of liberation of endotoxin during therapy for experimental Gram-negative bacterial sepsis. J. Infect. Dis. 151:1985;1012-1018.
22. Gemmel C., Lorian V. Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence, and susceptibility to immunodefenses: clinical significance. Lorian V. Antibiotics in Laboratory Medicine. 4th edition:1996;397-452 Williams and Wilkins, Baltimore, MD.
23. Neu H.C. Relation of structural properties of β-lactam antibiotics to antibacterial activity. Am. J. Med. 79(Suppl 2A):1985;2-13.
24. Dofferhoff A.S.M., Buys J. The influence of antibiotic-induced filament formation on the release of endotoxin from Gram-negative bacteria. J. Endotoxin Res. 3:1996;187-194.
25. Jackson J.J., Kropp H. Differences in mode of action of β-lactum antibiotics influence morphorogy, LPS release and in vivo antibiotic efficacy. J. Endotoxin Res. 3:1996;201-218.
26. Nakano M., Kirikae T. Biological characterization of Pseudomonas aeruginosa endotoxin released by antibiotic treatment in vitro. J. Endotoxin Res. 3:1996;195-200.
27. Eng R.H.K., Hsieh A., Smith S.M. Antibiotic killing of bacteria: comparison of bacteria on surfaces and in liquid, growing and nongrowing. Chemotherapy. 41:1995;113-120.
28. Cozens R.M., Tuomanen E., Tosch W., Zak O., Suter J., Tomasz A. Evaluation of bactericidal activity of β-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob. Agents Chemother. 29:1986;797-802.
29. Pucci M.J., Boice-Sowek J., Kessler R.E., Dougherty T.J. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob. Agents Chemother. 35(11):1991;2312-2317.
30. Hanberger H., Nilsson L.E., Kihlström E., Maller R. Postantibiotic effect of β-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP. Antimicrob. Agents Chemother. 34(1):1990;102-106.
31. Lorian V., Atkinson B. Abnormal forms of bacteria produced by antibiotics. Am. J. Clin. Pathol. 64:1975;678-688.
32. Georgopapadakou N.H., Liu F.Y. Penicillin binding proteins in bacteria. Antimicrob. Agents Chemother. 18:1980;148-153.
33. Periti P., Mazzei T., Mini E., Novelli A., Reali E.F. Attualità delle Cefalosporine in Chemioterapia. 1988;3-207 E.R.S, Firenze.
34. Satta G., Cornaglia G., Mazzariol A., Golini G., Valisena S., Fontana R. Target for bacteriostatic and bactericidal activities of β-lactam antibiotics against Escherichia coli resides in different penicillin-binding proteins. Antimicrob. Agents Chemother. 39(4):1995;812-818.
35. Gould I.M., MacKenzie F.M. The response of enterobacteriaceae to β-lactam antibitoics-'round forms, filaments and the root of all evil'. J. Antimicrob. Chemother. 40:1997;495-499.
36. Satta G., Fontana R., Canepari P. The two-competing site (TCS) model for cell shape regulation in bacteria: the envelope as an integration point for the regulatory circuits of essential physiological events. Adv. Microb. Physiol. 36:1994;181-245.
37. Fontana R., Valisena S., Cornaglia G. Comparative affinities for penicillin-binding proteins of multipolar ionic amphoteric cephalosporins in Gram-negative bacteria. J. Chemother. 8(Suppl. 2):1996;23-30.
38. Kahan F.M., Kropp H., Sundelof I.G., Birnbaum J. Thienamycin: development of imipenem-cilastin. J. Antimicrob. Chemother. 12:1983;1-35.
39. Soriano F. Optimal dosage of β-lactam antibiotics: time above the MIC and inoculum effect. J. Antimicrob. Chemother. 30:1992;566-569.
40. Sande M.A., Mandel G.L. Antimicrobial agents. General considerations. Gilman A.G., Goodman L.S., Gilman A. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th edition:1980;1080-1105 MacMillan, New York.
41. Ellner P.D., Neu H.C. The inhibitory quotient. J. Am. Med. Ass. 246:1981;1575-1578.
42. Soriano F., Ponte C., Santamaria M., Jimenez-Arriero M. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. J. Antimicrob. Chemother. 25:1990;621-627.
43. Hurley J.C. Reappraisal of the role of endotoxin in the sepsis syndrome. Lancet. 341:1993;1133-1135.
44. Holzheimer R.G. The significance of endotoxin release in experimental and clinical sepsis in surgical patients - evidence for antibiotic-induced endotoxin release? Infection. 26(2):1998;77-84.
45. Wiedemann B., Grimm H. Susceptibility to antibiotics: species incidence and trends. Lorian V. Antibiotics in Laboratory Medicine. 4th edition:1996;900-1168 Williams and Wilkins, Baltimore, MD.
46. Stratton C.W. Mechanisms of action for antimicrobial agents: general principles and mechanisms for selected classes of antibiotics. Lorian V. Antibiotics in Laboratory Medicine. 4th edition:1996;579-603 Williams and Wilkins, Baltimore, MD.
47. Smith I.I. Microbial surfaces in relation to pathogenicity. Bacteriol. Rev. 4:1977;475-500.
48. Brown M.R.W., Collier P.J., Gilbert P. Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies. Antimicrob. Agents Chemother. 34:1990;1623-1628.
49. Periti P. Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy. J. Chemother. 7(4):1995;311-337.
50. Finch R.G. In-vitro antimicrobial susceptibility testing: does it really matter? Introduction. J. Chemother. 9(Suppl. 1):1997;3-6.
51. Gould I.M. Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents. J. Chemother. 9(Suppl. 1):1997;74-83.
52. Li R.C., Zhu Z.Y. In vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective. J. Chemother. 9(Suppl. 1):1997;55-63.
53. Periti P. The chemotherapeutic formula revisited. Conclusions. J. Chemother. 9(Suppl. 1):1997;123-133.
54. Dofferhoff A.S.M., Esselink M.T., de Vries-Hospers H.G. et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J. Antimicrob. Chemother. 31:1993;373-384.
55. Bingen E., Goury V., Bennani H., Lambert-Zechovsky N., Aujard Y., Darbord J.C. Bactericidal activity of β-lactams and amikacin against Haemophilus influenzae: effect on endotoxin release. J. Antimicrob. Chemother. 30:1992;165-172.
56. Prins J.M., Van Deventer S.J.H., Kuijper E.J., Speelman P. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob. Agents Chemother. 38(6):1994;1211-1218.
57. Prins J.M., Van Agtmael M.A., Kuijper E.J., Van Deventer S.J.F., Speelman P. Antibiotic-induced endotoxin release in patients with Gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J. Infect. Dis. 172:1995;886-891.
58. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regiments for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:1995;89-96.
59. Schentag J. Pharmacokinetic issues and implications. 2nd European Congress of Chemotherapy and 7th Biennal Conference on Antiinfective Agents and Chemotherapy, May 10-13, 1998 Hamburg, Final Programme. Futuramed, Germany 1998:94.
60. Kirikae T., Kirikae F., Saito S. et al. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli. Antimicrob. Agents Chemother. 42(5):1998;1015-1021.
61. Van Langeveld P., Kwappenberg K.M., Groeneveld P.H.P., Mattie H., Van Dissel J.T. Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob. Agents Chemother. 42(4):1998;739-743.
62. Trautmann M., Zick R., Rukavina T., Cross A.S., Marre R. Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics. J. Antimicrob. Chemother. 41:1998;163-169.
63. Tuomanen E., Gilbert K., Tomasz A. Modulation of bacteriolysis by cooperative effects of penicillin-binding proteins 1a and 3 in Escherichia coli. Antimicrob. Agents Chemother. 30:1986;659-663.
64. Dofferhoff A.S., Esselink M.T., De Vries-Hospers H.G. et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J. Antimicrob. Chemother. 31:1991;373-384.
65. Mattie H., Razab Sekh B.A., Van Ogtrop M.L., Van Strijen E. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo. Antimicrob. Agents Chemother. 36(11):1992;2439-2443.
66. Pechère J.C., Wilson W., Neu H. Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. J. Antimicrob. Chemother. 36:1995;757-771.
67. Mock C.N., Jurkovich G.J., Dries D.J., Maier R.V. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch. Surg. 130:1995;1234-1241.
68. Then R.L., Anghern P. Ways to overcome cephalosporinase mediated β-lactam resistance in Enterobacter cloacae. Chemioterapia. 4:1985;83-93.
69. Pryka R.D., Haif G.M. Meropenem: a new carbapenem antimicrobial. Ann. Pharmacother. 28:1994;1045-1054.
70. Van Der Berg C., De Neeling A.J., Schot C.S., Hustinx W.N.M., Wemer J., De Wildt D.J. Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release. Scand. J. Infect. Dis. 24:1992;619-627.
71. Horii T., Kobayashi M., Sato K., Ichiyana S., Ohta M. An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of Gram-negative bacilli. J. Antimicrob. Chemother. 41:1998;435-442.
72. Thomas J.K., Forrest A., Bhavnani S.M. et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42(3):1998;521-527.
73. Moosdeen F., Williams J.D., Yamabe S. Antibacterial characteristics of YTR 830, a sulfone β-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob. Agents Chemother. 32(6):1988;925-927.
74. Yourassowsky E., Van Der Linden M.P., Lismont M.J., Crokaert F. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination. Chemotherapy. 36:1990;215-221.